Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7798176 | 0.80 | ALDH1A1 (0.47) | TSHRACHE | |
| SCHEMBL5153162 | 0.78 | CYP4F2 (0.41) | TSHRCYP4F2CYP4A11 | |
| SCHEMBL14108253 | 0.76 | TSHR (0.38) | TSHRACHECYP4F2CYP4A11 | |
| SCHEMBL13313707 | 0.76 | TSHR (0.38) | TSHRACHECYP4F2CYP4A11 | |
| SCHEMBL150006 | 0.75 | PRKCA (0.47) | TSHRACHECYP4F2CYP4A11 | |
| SCHEMBL12227045 | 0.75 | TSHR (0.41) | TSHRACHECYP4F2CYP4A11 | |
| Ammonia Solution, Strong SCHEMBL27804637 | 0.73 | PRKCA (0.45) | TSHRACHECYP4F2CYP4A11 | |
| SCHEMBL13589787 | 0.73 | TSHR (0.39) | TSHRACHECYP4F2CYP4A11 | |
| SCHEMBL15377575 | 0.72 | TSHR (0.37) | TSHR | |
| SCHEMBL852567 | 0.71 | CYP4F2 (0.42) | TSHRACHECYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050025826-A1 | Sustained release compositions, process for producing the same and utilization thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050025826-A1 | Sustained release compositions, process for producing the same and utilization thereof | HCAR1, HCAR2, LIPA | TSHR 3403/4885ACHE 1197/4885CYP4F2 1146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.